More Articles

Access and Evidence

Into pharma's roaring twenties

Paul Simms, (Jan 14, 2020)

A new decade is here. And despite the incredible science, pharma is ill-equipped.
Patients and Medical

Scaling patient engagement for deeper insights and better outcomes

Lucy Fulford, (Jan 13, 2020)

Scaling patient engagement offers a cascade of benefits if only pharma can gather the right insights
Patients and Medical

Pharma’s new ally: The caregiver

Andrew Stone, (Jan 12, 2020)

Pharma has only just started thinking about how engaging with caregivers could unlock a range of valuable insights
Access and Evidence

Advancing RWE together with academia

Katie Osborne, (Jan 2, 2020)

Pharma can realise the potential of RWE faster by collaborating more effectively with academia but first it must build trust

Invest in MSLs to reap bigger gains

Andrew Stone, (Dec 31, 2019)

To get the most from MSLs pharma needs to invest, measure and empower

Telemedicine: The future of clinical trials?

Nicola Davies, (Dec 13, 2019)

There is a new surge of interest in telemedicine’s potential to optimize clinical trials, but is this what patients want?
Patients and Medical

Patients united: Bringing the patient voice to genetics research

Nicola Davies, (Dec 5, 2019)

Parkinson’s disease genetic research has a powerful force to hand – an army of patients

Five eye-openers from the MIT Healthcare Panel

Paul Schrimpf, (Nov 28, 2019)

Modern pharma should not underestimate the importance of experience and culture in this age of innovation in R&D and data science
Access and Evidence

Prescription drug pricing: The times they are a changin’

Ulrich Neumann, (Nov 25, 2019)

The political mood in the US on drug pricing at a national and state level is putting the pressure on pharma to demonstrate value

Has direct to consumer marketing in pharma had its day?

Lucy Fulford, (Nov 25, 2019)

Outmoded and cliched DTC campaigns may be harming not helping pharma in the US